Amgen's PCSK9 outcomes trial to deliver data sooner than expected

The wait for outcomes data on Amgen's ($AMGN) PCSK9 drug Repatha just got shorter. As CardioBrief reports, top-line results of a study called Fourier will be available in the second half of 2016. If it's positive, expect broader use of the pricey PCSK9 class, which also includes Sanofi ($SNY) and Regeneron's ($REGN) Praluent. Report

Read more on